The Form 144 signals intent to sell a modest position relative to market cap. Monitor for actual Form 4 filings to confirm execution and watch for any additional insider sales or changes in company guidance that might explain the timing.
Price Chart
Executive Summary
Jay L. Geldmacher, a former REZI CEO and reporting owner of C4 Therapeutics, filed a Form 144 notice of intent to sell approximately 82,563 shares of common stock with an estimated aggregate market value of ~$1.9 million. The shares were acquired through restricted stock and performance share grants between 2024 and 2025. This is a relatively small sale relative to C4's $502M market cap, but the insider's role and the timing (no specific catalyst noted) warrant monitoring for potential follow-through sales or insider sentiment shifts.
Key Facts
- Jay L. Geldmacher filed Form 144 to sell up to 82,563 shares of C4 Therapeutics common stock.
- Estimated aggregate market value of the proposed sale is approximately $1,899,926.
- Shares were acquired via restricted stock and performance share grants dated 02/09/2025, 02/14/2025, 02/15/2025, 02/18/2024, and 02/14/2024.
- The filing date is August 14, 2026, with the proposed sale date also listed as August 14, 2026.
- The sale is planned through Morgan Stanley Smith Barney LLC Executive Financial Services.
Financial Impact
Proposed sale of ~82,563 shares valued at ~$1.9M, representing approximately 0.38% of C4's $502M market cap.
Risk Factors
- Insider sale may signal lack of confidence or personal liquidity needs; actual sale could pressure stock if executed in size.
- No specific catalyst identified; sale could be routine portfolio diversification.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-008190 |
| Document: 0001950047-26-008190-index.html | 0001950047-26-008190 |
| Document: 0001950047-26-008190.txt | 0001950047-26-008190 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 6w ago | 144 | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | $2.93 (−31.18%) |
Aug 14, 2026 6w ago | Institutional Cluster | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | $2.93 (−31.18%) |
Aug 11, 2026 7w ago | 8-K | $3.62 $4.18 | ▲ +15.47% | ▲ +15.87% | $2.93 (−18.92%) |
Jun 11, 2026 16w ago | Press Release | $3.87 $3.92 | ▲ +1.29% | ▲ +0.86% | $2.93 (−24.16%) |
May 15, 2026 19w ago | 8-K | $3.22 $3.49 | ▲ +8.39% | ▲ +6.77% | $2.93 (−8.85%) |
May 12, 2026 20w ago | 8-K | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | $2.93 (−7.41%) |
May 12, 2026 20w ago | Press Release | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | $2.93 (−7.41%) |
Apr 9, 2026 25w ago | 8-K | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | $2.93 (+3.71%) |
Apr 9, 2026 25w ago | Press Release | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | $2.93 (+3.71%) |
Mar 25, 2026 27w ago | Press Release | $2.69 $2.70 | ▲ +0.37% | ▲ +0.62% | $2.93 (+9.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access